How many mg of adagrasib is contained in each tablet?

Adagrasib is a targeted therapy drug specifically used to treat KRAS G12C mutation-positive non-small cell lung cancer (NSCLC). The drug is branded Krazati and was developed by Mirati Therapeutics. Adagrasiib achieves therapeutic effects by inhibiting the growth and spread of cancer cells caused by KRAS G12C mutations. It is the first drug approved by the FDA to treat this specific gene mutation, providing a new treatment option for patients with KRAS G12C mutation-positive lung cancer.

The common dosage form of adagrasib is oral tablets, each containing 200mg of the drug. This dosage form is suitable for long-term oral use, making it easier for patients to take medications on time at home and avoiding the discomfort that may be caused by injected drugs. Based on data from clinical trials, the standard recommended dosage is three tablets of 200 mg twice daily, for a total of 600 mg. Patients should conduct treatment under the guidance of a doctor to ensure the correct dosage and treatment cycle.

Adagrasiib tablets are immediate-release, white to off-white, oval in shape, with the words “200” printed on one side and the Mirati company logo printed on the other side. When taking, patients should swallow the tablets whole and should not chew, crush or split them to ensure stability and effective release of the drug. Typically, patients will receive regular follow-up visits and examinations during treatment to evaluate the effectiveness of the treatment and any side effects.

Although adagrasib has been widely used in the global market, it has not yet been officially launched in mainland China. Therefore, Chinese patients cannot purchase the drug directly through formal domestic channels. However, patients still have the option of obtaining adagrasib through overseas channels. Overseas drug sales platforms or international drug import channels are the main ways for patients to obtain drugs. When choosing these channels, patients should ensure that the sources of medicines are formal and safe to avoid encountering counterfeit medicines or substandard products.

The therapeutic effect of adagrasib has been confirmed in clinical studies. For KRAS G12C mutation-positive patients, adagrasib provides a new treatment option, especially those for whom other treatments are ineffective.

References:https://www.krazati.com/